Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare. Tokenization will enable qualified investors to directly invest in a single biotech product while preserving shareholder equity.
The growing adoption of blockchain technology, together with the latest financial regulatory changes, offers new alternatives to fund selected products with digital securities and opens an unprecedented opportunity to target financial investments in pharmaceutical product development.
Main Team (10)
Board of Directors (6)
BEST holders will benefit from downside protection provisions including a capital recall feature allowing them to reclaim a substantial portion of the original purchase price at any time following initial investment while retaining a stake in the security's upside that would result in a "make whole" outcome if the underlying project is successful.
An equity raise would be dilutive to all investors as it sells a portion of the of the entire company and its portfolio, whereas BEST provides investment in a specific product; hence providing existing investors full exposure to the rest of a company’s portfolio without the dilution typical of equity offerings.
BEST also provides BEST investors the ability to pick products of their interest for direct investment. For example, with our first BEST offering investors will have the opportunity to invest in our latest stage candidate (AGEN2034, our anti-PD-1 antibody).